Quantcast
Home > Quotes > ATNM

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock (ATNM) Quote & Summary Data

ATNM 
$0.5486
*  
0.0333
5.72%
Get ATNM Alerts
*Delayed - data as of Nov. 12, 2018  -  Find a broker to begin trading ATNM now
Exchange:AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
4
Today's High / Low
$ 0.598 / $ 0.5218
Share Volume
1,065,934
90 Day Avg. Daily Volume
1,223,387
Previous Close
$ 0.5819
52 Week High / Low
$ 0.8651 / $ 0.3323
Market Cap
61,070,969
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.59

Intraday Chart

Shares Traded

Share Volume:
1,065,934
90 Day Avg. Daily Volume:
1,223,387

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.25

Trading Range

The current last sale of $0.5486 is 65.09% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.598 $ 0.8651
 Low: $ 0.5218 $ 0.3323

Company Description (as filed with the SEC)

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and potentially commercializing targeted therapies for improved myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies are Antibody Radio-Conjugates, or ARC, that combine the targeting ability of monoclonal antibodies ("mAb") with the cell-killing ability of radioisotopes. Our ARC's have demonstrated the ability to improve access to bone marrow transplants with the potential for better outcomes, namely increased marrow engraftment and survival. Our product pipeline consists of two ARC product candidates that are currently being studied in three clinical trials. Two additional clinical trials are expected to begin patient enrollment in 2018. In each of the indications, we believe our product candidates are either first-in-class or have best-in-class potential.  ... More ...  


Risk Grade

Where does ATNM fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x